Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dipeptiven in Severe Traumatic Brain Injury
NCT02130674Phase 4Completed
- Sponsor
- University of Zurich
- Start
- Jan 2005
- Primary completion
- Feb 2011
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of alanyl glutamine in traumatic brain injury (TBI), sponsored by University of Zurich. Primary endpoints: Plasma glutamine levels and Cerebral glutamine levels. Started Jan 2005; status: completed.
02
Drugs
alanyl glutamine
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02130674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130674.